BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Purchased by Geneva Capital Management LLC

Geneva Capital Management LLC lifted its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 865,266 shares of the medical equipment provider’s stock after acquiring an additional 965 shares during the quarter. Geneva Capital Management LLC owned 1.88% of BioLife Solutions worth $21,666,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BLFS. Louisiana State Employees Retirement System raised its position in BioLife Solutions by 4.0% during the second quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after acquiring an additional 700 shares in the last quarter. GAMMA Investing LLC boosted its holdings in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 748 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in BioLife Solutions by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 753 shares during the period. Sei Investments Co. increased its holdings in BioLife Solutions by 1.4% in the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock valued at $1,117,000 after buying an additional 839 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of BioLife Solutions by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock worth $281,000 after acquiring an additional 1,374 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares of the company’s stock, valued at $2,883,097.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the sale, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,593,412.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,044 shares of company stock valued at $645,105. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Trading Down 0.4 %

BLFS stock opened at $26.50 on Wednesday. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average of $24.13 and a two-hundred day moving average of $22.72. BioLife Solutions, Inc. has a 12 month low of $9.92 and a 12 month high of $27.54.

Analyst Ratings Changes

A number of equities analysts have issued reports on BLFS shares. HC Wainwright assumed coverage on BioLife Solutions in a research report on Monday, September 30th. They set a “buy” rating and a $29.00 price target on the stock. TD Cowen upped their price objective on shares of BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. Northland Securities lifted their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, Craig Hallum upped their price target on shares of BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $26.67.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.